Real-world outcomes of pembrolizumab-chemotherapy combination in metastatic non-small cell lung cancer by age and sex: A national population-based study
{{output}}
Introduction: Lung cancer is the leading cause of cancer-related mortality worldwide. Immune checkpoint inhibitors (ICIs) are standard first-line therapy for metastatic non-small cell lung cancer (NSCLC), but real-world outcomes ... ...
